XP 400

Drug Profile

XP 400

Latest Information Update: 29 Jun 1999

Price : $50

At a glance

  • Originator XOMA
  • Class Antifungals
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 29 Jun 1999 Discontinued-Preclinical for Mycoses in USA (Unknown route)
  • 11 May 1999 No-Development-Reported for Mycoses in USA (Unknown route)
  • 03 Sep 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top